We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

PDE

Phosphodiesterase (PDE) inhibitors prevent the hydrolysis of cyclic nucleotides, second messengers of many receptors. The PDE superfamily comprises 11 families, PDE1 to PDE11, which differ in substrate preference, regulation and tissue distribution. Some families hydrolyze cyclic adenosine monophosphate (cAMP), others cyclic guanosine monophosphate (cGMP), and several act on both. By controlling the amplitude and location of these signals, PDEs shape inflammation, smooth muscle tone and cardiac function. PDE4 inhibitors in this category include roflumilast and apremilast, which are studied in inflammatory cell signaling. Sildenafil inhibits the cGMP-specific PDE5, and cilostazol is a PDE3 inhibitor. Ibudilast inhibits several families, including PDE3, PDE4, PDE10 and PDE11.

1 Item

  • MR-L2
    Cat. No.
    A41766
    CAS No.
    2374703-19-0

    MR-L2

    MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), specifically targeting PDE4A4, PDE4B1, PDE4C3, and PDE4D5 variants. This compound effectively inhibits PGE2-induced cyst formation in MDCK cells, exhibiting an EC50 of 1.2 μM. MR-L2 serves as a valuable tool for studying PDE4-related signaling pathways and exploring potential therapeutic applications in conditions involving dysregulated PDE4 activity.

    In stock View Details
    1 mg
    $120.00
    2 mg
    $180.00
    All 8 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...